| Company Name: |
Nextpeptide Inc |
| Tel: |
+86-0571-81612335 +8613336028439 |
| Email: |
sales@nextpeptide.com |
|
| | Hydroxy-PEG3-Mes Basic information |
| Product Name: | Hydroxy-PEG3-Mes | | Synonyms: | Hydroxy-PEG3-Mes;Hydroxy-PEG3-MS;Ms-peg4;CAS_139115-89-2;3,6,9-Trioxa-2-thiaundecan-11-ol, 2,2-dioxide;2-(2-(2-Hydroxyethoxy)ethoxy)ethyl methanesulfonate | | CAS: | 139115-89-2 | | MF: | C7H16O6S | | MW: | 228.26 | | EINECS: | | | Product Categories: | | | Mol File: | 139115-89-2.mol |  |
| | Hydroxy-PEG3-Mes Chemical Properties |
| Boiling point | 398.2±27.0 °C(Predicted) | | density | 1.256±0.06 g/cm3(Predicted) | | pka | 14.36±0.10(Predicted) | | form | Liquid | | color | Colorless to light yellow |
| | Hydroxy-PEG3-Mes Usage And Synthesis |
| Uses | Hydroxy-PEG3-MS is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1]. | | Biological Activity | Hydroxy-PEG3-MS is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1].
PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1]. | | IC 50 | PEGs | | References | [1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562 |
| | Hydroxy-PEG3-Mes Preparation Products And Raw materials |
|